Activaero Appoints Dr Ulrich Dauer as Chief Strategy Officer

Activaero GmbH, the therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions for severe lung diseases, has appointed Dr Ulrich Dauer as Chief Strategy Officer. He joins at a time when the Company is progressing fastly towards the filing for approval of its lead product for the treatment of severe asthma, FAVOLIR, in Europe. He will be responsible for the company's corporate development strategy and the implementation of the respective financing needed.

Through his previous position as founding member and CEO of the discovery and development company 4SC AG since 2000, Dr Dauer is a well-known executive in the healthcare industry as well as in the financial community. Following the listing of 4SC in the Prime Standard of the Frankfurt Stock Exchange in 2005, he has designed and established the Company's growth strategy based on collaboration and licensing partnerships with international pharmaceutical and biotech companies and fund raisings via capital markets with a combined volume of EUR 150 million. Dr Dauer received his PhD from the Institute of Organic Chemistry at the University of Wuerzburg.

"As Activaero is facing a variety of strategic options with the fast progress we are making in our programmes, we are warmly welcoming Ulrich with his experienced leadership personality," commented Dr Gerhard Scheuch, Founder and Chief Executive Officer of Activaero GmbH. "In his previous position, he successfully demonstrated that he can lead a company through a period of accelerated growth, providing access to capital markets and always focusing on a well-balanced risk-reward ratio. Furthermore, his international network in industry and finance is of great value to us."

"Activaero is currently one of the most exciting life sciences companies," said Dr Ulrich Dauer, Chief Strategy Officer of Activaero GmbH. "The Company's proprietary inhalation approach addresses a high medical need in the growing market of respiratory diseases. Since the company's innovative therapies are based on highly efficacious but therapeutically not fully exploited drugs without the digital risk of novel drug development, the equity story is highly attractive for today's investors. I am excited to become part of the team at a pivotal phase of the company's development and make my contribution to Activaero's further progress."